Use of a tube spacer to improve the efficacy of a metered-dose inhaler in asthmatic children
G. S. Rachelefsky, A. S. Rohr, J. Wo, V. Gracey, S. L. Spector, S. C. Siegel, R. M. Katz and M. R. Mickey
Many children with asthma do not use the standard metered-dose inhaler
(MDI) skillfully. To improve drug delivery, correct problems of hand-lung
incoordination, and reduce local side effects, a number of spacer devices
have been developed. We evaluated one such device, a tube spacer
(Aerochamber), in 16 asthmatic children (5 to 12 years). On four separate
days and in a randomized, double-blind, placebo-controlled manner, they
received either metaproterenol sulfate by MDI aerosol (130 micrograms) or
placebo with and without the tube spacer. To maximize techniques, at each
visit the children had proper instructions, including viewing a videotape.
Spirometry was performed at baseline and 5, 15, and 30 minutes, and hourly
for six hours, and the patient was monitored. Analysis of the entire group
(forced expiratory volume at 1 s and midmaximal expiratory volume) revealed
no difference between metaproterenol administered with or without the tube
spacer, and both were significantly different than placebo through two
hours. Six children had longer and three had better bronchodilatation with
the MDI plus tube spacer than with the MDI alone. Side effects and vital
signs did not differ between treatments. Under the circumstances of our
study, the tube spacer device might enhance the use of the MDI in children
who are not properly taught and/or who forget or cannot perform proper
technique.
